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Abstract: 
 
Antidepressants effectiveness in Major Depressive Disorder (MDD) is still questioned 
because the extrapolation of Randomized Controlled Trial (RCT) results to “real life” settings 
is problematic. The application of the RCT paradigm in a disorder of this type, where global 
care plays a central role, raises questions regarding the internal and external validity of this 
type of study. Outcome measurement, attrition rates, the ability of the double-blind design to 
control for expectations, placebo response, the representativeness of trial participants and 
publication bias are major methodological pitfalls. This review discusses these issues. It is 
illustrated using original data and proposes some alternatives for assessing antidepressant 
effectiveness via different approaches. Some are easy to implement, such as ecological 
measures, qualitative approaches, improvement of analytical strategy and improvement of 
blinding procedures. Some are sophisticated, involving temporary deception to deal with the 
counfounding effect of expectations, and they raise ethical issues. Others resort to external 
validity, this being the case in observational studies. But all are necessary to explore 
antidepressant effectiveness. 
 
 
Keywords: antidepressants, clinical trials, depression, effectiveness, methodology  
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Introduction 
 
The usefulness of Antidepressants in major depressive disorder is still questioned (Ioannidis, 
2008) and the issue goes beyond the scientific debate, with a backdrop of conflicts of interest 
and some concerns about the medicalisation of modern society (Lacasse and Leo, 2005). The 
usefulness of a drug is usually reflected by its efficacy (under optimal circumstances), its 
effectiveness (in routine care), and its efficiency (does it maximize value for money?) 
(Bombardier and Maetzel, 1999). Among these concepts, effectiveness seems to be the most 
relevant question for clinicians. Randomised controlled trials (RCTs) are generally used to 
address this issue.  
Since the first published RCT versus placebo to explore the efficacy of streptomycin in 
tuberculosis (1948), this design has become a gold standard. But tuberculosis is quite different 
from a mood disorder that fits a bio-psychosocial model (Garcia-Toro and Aguirre, 2007), 
where therapeutic benefits could result from the context in which the study is performed. 
Global care (including the ethical meaning of this term) (Beauchamp and Childress, 2008) 
plays a central role, and psychological factors such as expectations may influence the results. 
Outcome definition, analysis and extrapolation of the results are likewise somewhat specific 
in mood disorders.  
The NICE guidelines on the treatment and management of depression in adults 
(NationalInstituteforClinicalExcellence, 2010) advise caution when considering the 
application of RCTs results in routine practice, and suggests that better ways of assessing 
effectiveness have yet to be developed.  
The present paper has two aims: 1/ To present various methodological shortcomings in the 
evaluation of antidepressant effectiveness concerning internal (reliability of the results) and 
external (scope for generalisation) validity of trials, which are two fundamental inter-
connected and sometimes contradictory guarantees. 2/ To present certain alternatives to 
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address these issues in order to achieve a balance between these two concepts. We have 
illustrated our reflexion with secondary analyses from a previous meta-analysis (Naudet et al., 
2011).  
1. Methodological issues 
1.1. Outcome measurement and analysis is problematic 
Outcome measurement 
 
The efficacy of antidepressants is assessed using continuous outcomes (the mean change on a 
scale), or categorical outcomes (response rate and remission rates).  
Concerning continuous outcomes, the HDRS (Hamilton, 1960) and the MADRS 
(Montgomery and Asberg, 1979) are recognized as gold standards (Duru and Fantino, 2008). 
Nevertheless they can show up differences that are statistically significant in formal terms 
even for differences that are not significant from a clinical point of view (Ioannidis, 2008): the 
identification of a minimum clinically relevant difference is not straightforward (Falissard et 
al., 2003). In addition, they contain items that are not specific to depression (sleeping 
difficulties, anxiety, agitation and somatic complaints) and may highlight non-mood-related 
benefits (Moncrieff, 2002). Moreover, these scales tend to be used by tradition rather than 
because of their perfect validity and reliability. For example, a review showed that the HDRS 
was not optimal psychometrically and was conceptually flawed (Bagby et al., 2004).  
The Clinical Global Impression (Guy, 1976) (CGI) is used as a global assessment. It 
comprises a single item with high “face validity”, but it may be more prone to rater bias 
(Gaudiano and Herbert, 2005). Its validity is debated mainly because the response format used 
in the CGI is more likely to be ambiguous (what is the definition of a patient who is "Severely 
ill"?) and is prone to cultural misunderstanding (for example concerning the meaning of 
"moderate") (Kadouri et al., 2007).  
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The scales considered here are clinician-version evaluations, while self-administered 
questionnaires like the Beck Depression Inventory (Beck et al., 1961) (BDI) or ecological 
measures such as computerised assessments of depression (Greist et al., 2002; Mundt et al., 
2006) are far from being systematically reported in antidepressant studies.  
Clinicians, in their day-to-day practice, are used to dealing with binary outcomes such as 
response and remission, which have considerable prognostic value (Judd et al., 1998). 
Although these concepts appear intuitive, no real gold standard exists and categorical 
outcomes are generally calculated from continuous data, and are provided by the proportion 
of people who meet a predefined level of improvement (response) or fall below a predefined 
threshold score (remission) at a given time point. This does not take into account the 
longitudinal aspect of these concepts, and creates the impression of clear-cut patterns where 
the data does not suggest any. This phenomena is interpreted as a major bias (Kirsch and 
Moncrieff, 2007) or as proof of antidepressant effectiveness (Gibbons et al., 2012) depending 
on the authors' preconceived beliefs.  
Attrition rates 
 
Among patients enrolled in a RCT, typically 20 to 40% fail to complete the study. Whereas a 
loss to follow-up of 5% or lower is usually of little concern, a loss of 20% or more prevents 
good quality intention-to-treat (ITT) analysis, can cause biased estimates of the treatment 
effect (Dumville et al., 2006) and restricts the scope for generalising results (Leon et al., 
2006). The two approaches to the analysis of incomplete data used in most of the studies by 
which efficacy of new-generation antidepressants is established (conducted between 1990 and 
2010) are far from ideal: 1/ complete case analysis assumes that missing data are “Missing 
Completely At Random” (dropout is unrelated to the phenomenon studied or to patient 
characteristics) which is not likely to be valid. 2/ the last observation carried forward (LOCF) 
procedure, which is the most frequently used method, negatively impacts treatment arm 
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results since dropouts are assumed not to improve beyond their removal from the study. It 
ignores the natural history of MDD (Posternak et al., 2006). Differential dropout rates 
between groups may artificially inflate the superiority of one study condition over another. 
This method does not incorporate the uncertainty surrounding the imputed data in the analyses 
(Leon et al., 2006).  
Regarding categorical outcomes, the maximum bias hypothesis (non-assessed patients are 
recorded as in remission if they belong to the placebo group and as having not responded if 
they belong to the antidepressant group) could be considered as the most complete and 
accurate measure of robustness for an analysis. It is rarely performed in MDD trials. In fact it 
leads to the reverse conclusion (placebo superiority) as shown in table 1. 
 Insert table 1 about here.    
1.2. The response rate in the placebo group affects internal validity 
Response rate in placebo group 
 
Response in the placebo group is substantial in RCTs on antidepressants and has led to many 
negative trials (Enserink, 1999). Evidence of an increasing placebo response rate over the 
years has been documented (Walsh et al., 2002) and justifies the continued use of placebo-
control trials even if there are a number of proven treatments for MDD (Benedetti et al., 
2005). However, the cause of this increase is unclear; it could be hypothesised that increasing 
antidepressant availability, greater social acceptability (Olfson et al., 2002) and the changes in 
the methods by which patients are recruited into therapeutic trials (Walsh et al., 2002) could 
have resulted in changes in clinically important population characteristics (for example 
outpatients with less severe episodes) and could have contributed to changes in the placebo 
effect. Moreover, expectations about the therapeutic benefit of treatment may have changed 
and could affect the results of antidepressant RCTs (Krell et al., 2004; Noble et al., 2001; 
Rutherford et al., 2010; Sotsky et al., 1991) because they are linked with the placebo effect.  
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Meta-analyses (Fournier et al., 2010; Khan et al., 2002; Kirsch et al., 2008) suggest that the 
baseline severity of depressive symptoms is related to clinical trial outcome. The minimum 
baseline HDRS score needed to reach a clinically meaningful difference between 
antidepressant and placebo was found to be approximately 28 (very severely depressed 
patients) (Kirsch et al., 2008) or 25 (Fournier et al., 2010). Despite disagreements regarding 
whether the increasing superiority of antidepressants relative to placebo as severity increases 
is due to an increasing efficacy of antidepressants or a declining efficacy of placebo, the 
association between the drug-placebo difference and baseline severity is consistent and robust 
in the different meta-analyses.  
Placebo response and internal validity 
 
Randomisation (Vandenbroucke, 2004) is a cornerstone of internal validity: it enables 
unbiased allocation of treatment (Schulz and Grimes, 2002) and complies with statistical 
theory for random sampling. Blind allocation of treatment makes it possible to infer the 
specific treatment effect, thus addressing the problem of patient expectations (Fisher, 1971). 
However, regarding antidepressants, the ability of a double-blind design to preserve the 
benefit of randomisation is disputed (Perlis et al., 2010). The first reason is that the majority 
of patients and doctors correctly distinguish between placebo and active medication 
(Bystritsky and Waikar, 1994; Rabkin et al., 1986): this will be referred to as “unblinding”. 
For instance the blinding could be compromised by the emergence of adverse effects (Perlis et 
al., 2010) known to be associated with a specific medication; informed consent forms, which 
list common adverse effects, may increase this risk (Brownell and Stunkard, 1982). Moreover, 
the possibility of belonging to a placebo group could lead to lower expectations of how much 
a patient is likely to improve during the trial. The likelihood of response and remission is 
significantly higher in comparator versus placebo-controlled trials (Naudet et al., 2011; 
Rutherford et al., 2010; Rutherford et al., 2009; Sinyor et al., 2010; Sneed et al., 2008). This 
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phenomenon could be differential between antidepressant arms and placebo arms: a greater 
probability of receiving placebo predicted a greater antidepressant efficacy versus placebo 
(Papakostas and Fava, 2009), without influencing attrition rates (Tedeschini et al., 2010). This 
has methodological implications since it could lead to an under-estimation of the placebo 
effect in placebo-controlled trials, and ethical consequences because patient improvement in 
such studies is poorer.  
It has been hypothesised by certain authors that the apparent antidepressant effect is actually 
an active placebo effect (Kirsch and Sapirstein, 1998) (the different physiological experiences 
resulting from the ingestion of an active drug and an inert placebo may lead patients and 
assessors to suspect the nature of the medication and this will then introduce bias due to 
different expectations for treatment effect).  
Understanding the placebo response 
 
While a high response rate in a placebo group is a major methodological problem, there is 
considerable debate about the size, the nature and the mechanism of the placebo effect in 
depression. The placebo effect is quite difficult to define and has two main interpretations: the 
effect of the placebo intervention, and the effect of patient-provider interaction.  
In a first approach, the effects of a placebo can be estimated as the difference between the 
placebo arm and a no-treatment arm. A meta-analysis utilizing a controversial approach found 
that a placebo effect accounted for about 50 % of the response, “natural history” for about 
25% and antidepressant effect for 25 % (Kirsch and Sapirstein, 1998). In contrast, in another 
controversial and underpowered meta-analysis of RCTs of placebo versus no-intervention 
(Hrobjartsson and Gotzsche, 2010), there was no statistically significant effect of placebo 
interventions in depression.  
Beyond these two contrasted approaches, scientific knowledge about the placebo effect in 
MDD is derived from RCTs, which are pragmatic and compare an antidepressant to a placebo 
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in order to prove the superiority of the antidepressant, regardless of the underlying 
mechanisms. The calculation of the antidepressant–placebo difference by comparing marginal 
response rates is thus based on the postulate that all placebo responders should be 
antidepressant responders (additive model, Figure 1) whereas theoretically, antidepressant 
response and placebo response could be independent or, at least, substantially overlapping 
phenomena (non-additive model, Figure 2) with four different types of patients : 1/ placebo-
only responders 2/ treatment-only responders 3/ placebo and treatment responders and 4/ non-
responders (Kirsch, 2000; Rihmer and Gonda, 2008). It is also noteworthy that RCTs 
endeavour to reduce placebo effect, typically by eliminating subjects who show a strong 
placebo response before randomization (Benedetti et al., 2005; Muthen and Brown, 2009). 
These different aspects limit our understanding of the placebo effect. 
Moreover response to placebo is not  strictly a placebo effect (the psychobiological reaction to 
the administration of an inert treatment based on expectation and conditioning or other 
learning processes) (Ernst and Resch, 1995; Finniss et al., 2010):  the clinical improvement 
following administration of a placebo (placebo response) could result from many different 
factors, such as spontaneous improvement (Posternak and Zimmerman, 2000), statistical 
regression to the mean, co-interventions, biases as well as the placebo effect. Indeed, 
spontaneous improvement can result from environmental or biological (e.g. seasonal) factors 
which afford scope for scientific investigation. Spontaneous improvement may be common in 
clinical practice (Posternak et al., 2006; Posternak and Zimmerman, 2000) ; the number of 
follow-up assessments (Posternak and Zimmerman, 2007) is related to a significant 
therapeutic effect.  
1.3. The extrapolation of RCT results is problematic 
External validity of RCTs in Major Depressive Disorder 
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Whilst the vast majority of patients with clinical depression are catered for in primary care, 
most of the research findings upon which decisions are based have involved secondary care 
patients. In a Cochrane Review, the authors found only fourteen studies versus placebo in 
primary care with extractable data, of which ten studies examined tricyclic agents, two 
examined SSRIs and two included both classes (Arroll et al., 2009). This contrasts with a 
plethora of literature on antidepressants in secondary care outpatients. These patients differ 
from primary care patients (Araya, 1999; Suh and Gallo, 1997): they are less severely 
depressed, experience a milder course of illness, have a distinct symptom profile with more 
complaints of fatigue and somatic symptoms, and are more likely to have accompanying 
physical complaints (Linde et al., 2011). 
Antidepressant RCTs use numerous exclusion criteria (comorbid medical condition, short 
duration of depressive episode, comorbid personality disorder, mild depression, treatment 
response during placebo lead-in period, comorbid anxiety disorder, long duration of 
depressive episode, comorbid substance use disorder, prior non-response to treatment, 
comorbid dysthymia, current suicidal ideation). Some of these criteria are arguable from a 
fundamental viewpoint. Efficacy trials are designed to answer specific questions and they are 
required to investigate the disorder independently from co-morbidities, which undoubtedly 
affect response, depending partly on the agent tested: for example, the fact that 
antidepressants have anxiolytic effects justifies the exclusion of comorbid anxious disorders 
so as to explore efficacy in depression on its own. Nevertheless, this greatly reduces scope for 
generalisation (Posternak et al., 2002) in a disorder where comorbidity is the rule and a 
conclusion of effectiveness should not derive solely from these studies.  
Subjects treated in antidepressant trials represent a minority of patients treated for MDD in 
routine clinical practice (Zimmerman et al., 2002). One study among psychiatric outpatients 
suggests that patients that were excluded were a more chronically ill group with more 
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numerous previous episodes, greater psychosocial impairment, and more frequent personality 
disorders (Zimmerman et al., 2005). Furthermore, participants are generally recruited by 
newspaper advertisement, paid for their participation in the study and may not be 
representative of “real life” patients (Greist et al., 2002). Even the main inclusion criterion 
(i.e. suffering from MDD) could reduce the external validity of such studies since there could 
be deficits in knowledge and in the application of this criterion by clinicians (Zimmerman and 
Galione, 2010).  
Some data suggest that antidepressants may not or not adequately assist recovery in a “real 
life” setting (Brugha et al., 1992; Ronalds et al., 1997). In a retrospective analysis of a cohort 
of inpatients (Seemuller et al., 2010), patients eligible (applying classic inclusion criteria) for 
a RCT and patients not eligible differed significantly for several baseline measures and for 
final Global Assessment of Functioning scores, but not for any other outcome measure, such 
as depression rating scores. However, this study only recruited inpatients (a more 
homogenous population) and the analysis was not adjusted on prognostic factors at baseline or 
on associated treatment.  
In another similar analysis applied to an outpatient cohort (Wisniewski et al., 2009), patients 
eligible for a RCT had a better response to treatment, which persisted even after adjustments 
for baseline differences. The design of this study provides a better control for confounders. A 
meta-regression comparison (Naudet et al., 2011) showed that antidepressant response is 
lower in observational studies compared to RCTs. This result has recently been replicated 
(van der Lem et al., 2012). 
Finally, RCTs typically last 6-8 weeks whereas it is recommended that an antidepressant 
treatment be continued for at least 6 months after remission of the episode of depression 
(NationalInstituteforClinicalExcellence, 2010). 
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Meta-analysis limitations  
 
The limitations of a meta-analysis are linked to the limitations of the individual studies 
included (Egger et al., 2001) and all the above-mentioned methodological problems have to 
be considered. Moreover, most studies on the effects of drugs are sponsored by the 
pharmaceutical industry. These studies have been shown to be more likely to demonstrate 
positive effects for the sponsor’s drug than independent studies (Lexchin et al., 2003). When 
meta-analyses are not based on registered trials (e.g. FDA-registered trials), a publication bias 
can occur (Turner et al., 2008). It has been shown that the publication bias can lead to 
considering reboxetine as a serious antidepressant agent, whereas it is probably an ineffective 
and potentially harmful antidepressant (Eyding et al., 2010). Since 2005, RCTs need to be 
registered prior to participant enrolment, but two points could be improved: unpublished but 
registered study results must be accessible and selective outcome reporting (Mathieu et al., 
2009) must be avoided.  
These considerations should lead to caution in the interpretation of efficacy meta-analyses, 
and also in interpretation of meta-analyses concerning the influence of methodological factors 
(Huf et al., 2011). These are precisely some of the studies on which some of the above 
remarks are based. It gives an idea of the uncertainty surrounding the discussion presented 
here.  
Insert table 2 about here. 
Table 2 illustrates all the points discussed above with a descriptive analysis of 26 randomized 
controlled trials on venlafaxine or fluoxetine.  
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2. Methodological alternatives to answer the question of 
antidepressant effectiveness 
2.1. Improving outcome measurement and analysis 
Outcome measurement 
 
Determination of the effectiveness of antidepressants should not be based exclusively on mere 
interviewer ratings of outcome, which can be prone to statistical noise and/or bias. A more 
robust approach is needed, and outcomes should be assessed in multi-modal fashion 
(Gaudiano and Herbert, 2005).  
Categorical outcomes like response and remission should not be exclusively calculated from 
continuous data such as the HDRS (Kirsch and Moncrieff, 2007).  
Assessment of categorical self-report (remission and response) using valid instruments is 
needed for sensitivity analysis. It has been suggested that depressed patients consider 
symptom resolution as only one  of the factors in determining the state of remission, and that 
the presence of positive features of mental health such as optimism, vigor, and self-confidence 
is a better indicator of remission than the absence of the symptoms of depression 
(Zimmerman et al., 2006). 
Furthermore these two concepts should not be assessed at a single time point but should 
address the question of passing time, and whether there is stability over several weeks 
(Bandelow et al., 2006). Continuous (BDI), collateral information, behavioural ratings and 
physiological indices should be obtained to complete the information derived from clinician-
rated scales and to examine convergence of these data (Petkova et al., 2000).  
Finally, the use of qualitative approaches should be developed in RCTs (Lewin et al., 2009) 
and could be of interest in antidepressant trials to understand the effects of interventions and 
to focus on patients’ experiences, as these processes are difficult to explore using quantitative 
methods alone. Mixed (qualitative-quantitative) methods could be of interest in this way 
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(Falissard et al., Submitted). The procedure is simple, and is at present under development: 
video-interviews based on the iCGI procedure (Kadouri et al., 2007) are performed and are 
randomly shown in a blind manner to different groups of raters (experts, clinicians or medical 
students...) who classify them according to whether the patient received a placebo or an 
antidepressant. The test is a permutation test. It enables the identification of differences 
between groups. A qualitative analysis of the videos will enable comparison of the 
experiences of patients under antidepressants and under placebo in a phenomenological 
perspective. This would also enable a broader measurement of adverse outcomes including 
unwanted psychological effects as an important aspect, which could contribute to a more fine-
grained comparison of conditions. In addition it tackles the limitations of the CGI mentioned 
above. 
 Attrition rate management could be improved 
 
Before dealing with missing data, it is important to prevent them. Nevertheless, “attrition-
reduced studies” can present problems for generalisation to clinical practice where the 
attrition rate is high. We therefore recommend that for patients who are lost to follow up, an 
effort should be made to obtain the principal outcome without interfering with their adherence 
to treatment using more accessible assessments by telephone (Greist et al., 2002) or home 
visits: investigators should try to obtain complete follow-up data on all subjects, irrespective 
of their adherence to the treatment protocol (Lavori, 1992).  
Secondly, the outcomes of subjects who withdrew should be described and compared to those 
of completers (Dumville et al., 2006). Concerning the handling of missing values, no 
universally applicable method can be recommended. Nevertheless, it should be well thought 
out, and pre-defined in the protocol. Three general approaches to the analysis of incomplete 
data can be used: 1) analysis of complete cases; 2) missing data imputation (LOCF or multiple 
imputation); and 3) analysis of incomplete data (survival analysis, mixed model, model of 
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missingness). ITT analysis should, as in all RCTs, be the rule for the main analysis. Here, 
mixed-effect models are useful because subjects who have missing data are not completely 
excluded from the analyses and the missing data are not imputed.  Nevertheless, it is 
performed under the Missing At Random hypothesis (i.e. "missingness" is explained by 
observed outcomes or covariates, presumably pre-dropout, but not unobserved outcomes). 
This type of analysis is therefore likely to favour arms with attrition. Finally, collecting data 
that can help predict attrition, for instance by asking participants to rate the likelihood of 
attending the subsequent assessment session, can change the problem of dropout from Not 
Missing at Random (i.e. missingness is explained by unobserved outcomes) to Missing At 
Random, but this should be used cautiously in the analysis of data (Leon et al., 2006).  
Multiple imputation (Little and Rubin, 1987) procedures assume that data are Missing At 
Random: all non-missing values of outcomes at all time points and baseline demographics are 
used in the models, which generate imputed estimates. Generally, 5 imputation data sets are 
generated and estimates are combined so that standard errors reflect the variability introduced 
by the imputation process.  
Present-day studies tend to implement these two approaches (Lynch et al., 2011) whereas 
other analyses such as “completer-only analysis”, LOCF and analysis under the maximum 
bias hypothesis are used as sensitivity analyses to assess the robustness of the analytical 
strategy. 
2.2. Controlling for the placebo response 
Placebo response improvement should be sought in effectiveness 
studies 
  
RCTs versus placebo aim to reduce the placebo effect, whereas in day-to-day clinical practice, 
everything is done to enhance placebo effect. Thus to asses antidepressant effectiveness it is 
reasonable to consider certain adjustments and explanatory designs potentiating the placebo 
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effect in depression, allowing comparison with conditions that mimic all the theoretically 
important elements of placebo response associated with pharmacotherapy (e.g., expectation of 
improvement, doctor involvement and contact, credible treatment rationale...) (Gaudiano and 
Herbert, 2005).  
As the risk of unblinding is substantial an assessment of the integrity of double-blind 
procedures should be performed routinely (Antonuccio et al., 1999; Even et al., 2000) by 
asking clinicians and patients to report the study condition to which they think or guess they 
have been assigned. Concerning clinician rating scales, keeping raters blind to the study 
design and hypothesis can protect against bias from their expectations.  
Multi-arm studies where different doses that may or may not be effective are used alongside a 
similar active comparator and placebo can address this question. Nevertheless, such studies 
are not valid when side effects are dose-dependent. The use of an “active” placebo, with side 
effects mimicking those of the active drug, has been proposed. This method was developed in 
the early days of antidepressant research, but is rarely used in modern psychotropic studies 
(Perlis et al., 2010). A meta-analysis of antidepressant trials using active placebos suggested 
smaller effect sizes than those observed in the presumably less blinded trials using inert 
substances (Moncrieff et al., 2004). However, the ability of a design of this sort to prevent 
unblinding is not established, as the raters were able to guess better than by chance what 
medication the patients were taking (Uhlenhuth and Park, 1964; Weintraub and Aronson, 
1963).  
Thus a four-arm “balanced placebo trial design” using antidepressants, active placebo controls 
and intentional deception of subjects (patients are given information in a way that produces 
false beliefs) in a latin square design has been proposed (Kirsch and Sapirstein, 1998) (Figure 
3) and this could diminish the ability of subjects to discover the study condition to which they 
have been assigned. Subjects are randomised in four arms: 1/ a “deception” arm where 
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patients receive the real drug and they are told they are receiving a placebo 2/ a “deception” 
arm where the patients receive the active placebo and are told they are receiving the real drug 
3/ a “non-deception” arm where patients receive the real drug and they are told they are 
receiving the real drug 4/ a “non-deception” arm where the patients receive the active placebo 
and are told they are receiving the placebo. This design makes it possible to distinguish 
between an additive model and a non-additive model. Nevertheless, using an active placebo 
deliberately induces risk of adverse effects (even if they are benign or even potentially 
therapeutic) and this is an ethical problem (Perlis et al., 2010). The “balanced placebo trial 
design” has not yet been used in clinical trials on antidepressant medication, because of the 
ethical issues involved with temporary deception (Dowrick et al., 2007; Waring, 2008).  
 
Alternatives designs to control for expectations 
 
However, as in standard trials unblinding can be highly problematic, temporary deception is a 
key point in controlling for expectations (because accurately informing subjects could bias 
response to treatment). Although its mechanisms are unclear, it is undeniable that deception is 
a key element in placebo potency (Lakoff, 2002). Two approaches have been suggested to 
minimize the ethical difficulties linked to temporarily deceiving subjects (Dowrick et al., 
2007): 1/ pre-consent (subjects are informed that the study involves deception, and are asked 
to consent to its use, without being informed of the nature of the deception) and 2/ 
“minimised” deception. This can take the form of a three-arm randomised controlled trial in 
which the effects of placebo, active medication, and usual care are examined and where there 
is temporary deception concerning the placebo arm (Figure 4). Patients are told that they will 
be randomized to receive “usual care + nothing” or “usual care + antidepressant”. Pre-consent 
(1/) (Wendler and Miller, 2004) (“You should be aware that the investigators have 
intentionally left out information about certain aspects of this study”) respects the subject's 
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autonomy but could reduce the pragmatic effectiveness of the study because participants may 
guess the nature of the deception. “Minimised” deception (2/) is likewise possible because the 
information given about risk and benefit in the “usual care + nothing” group at the time when 
they provide consent is correct, but this nevertheless provides a placebo group. In both cases, 
the subjects are informed of the nature of the deception at the end of their participation.  
This design is useful to preserve the methodological benefit of randomisation and to obtain an 
unbiased assessment of the benefit of the antidepressant against the placebo and the benefit of 
the placebo against nothing. Certain criteria may justify deceiving the patient: 1/ The use of 
deception is necessary and no equally effective, non-deceptive approach is feasible, 2/ the use 
of deception is justified by the study’s social value, 3/ subjects are not deceived about aspects 
of the study that would affect their willingness to participate, including potential risks and 
benefits, 4/ subjects are informed of the nature of the deception at the end of their 
participation and 5/ in case of pre-consent, subjects are informed prospectively of the use of 
deception and consent to its use (Wendler and Miller, 2004).  
Nevertheless, another objection against studies involving deception is the risk of 
psychological harm to research participants (Bortolotti and Mameli, 2006). A number of 
studies performed among healthy volunteers participating in psychology experiments have 
found that being deceived does not upset most subjects (Wendler and Miller, 2004) but the 
impact of a design that involves deceiving subjects among depressive patients is not known. It 
could undermine patients’ trust in physicians in general, as has been suggested in a qualitative 
study (Dowrick et al., 2007). Thus if a trial uses deception techniques, investigators should 
obtain data on the impact of the deception on mood and the therapeutic alliance.  
Even if they do not provide the same information, alternative trial designs can be considered. 
One option is to adopt a design in which all study participants are informed that they will start 
with a placebo and that an active drug may be substituted after a while and that they may (or 
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may not) be informed when this switch is made. This protocol could provide information for 
three of the four arms of the balanced placebo design without any deception being required - 
the exception being “told drug/no drug”- (Colloca et al., 2004; Dowrick et al., 2007). 
Nevertheless, it is prone to “unblinding” because subjects can guess when the switch is made, 
even if they are not told. 
Another design to preserve the benefit of randomisation could be a non-inferiority study 
comparing a placebo (presented as a new therapeutic alternative with fewer side effects) to an 
active antidepressant. This design is well justified for patients with a baseline HDRS score of 
25 which was identified as the score needed to reach a clinically meaningful difference 
(Fournier et al., 2010). Here there is no deception because in this case, the placebo is a real 
therapeutic alternative. Nevertheless, an inclusion criterion of this sort limits the scope for 
generalising the results. 
In this respect, it has been recently argued that consent forms in RCTs versus placebo should 
generate positive expectations regarding the possible effect of a placebo (spontaneous 
improvement without the use of medication) to reduce patient fears of a negative outcome 
following study participation (Severus et al., 2012).   
Another idea could be a double-blind trial comparing an antidepressant to homeopathy. In 
major depressive disorder, there is not enough evidence about the efficacy of homeopathy 
(Pilkington et al., 2005) but it elicits expectations in patients and could be considered as a 
good comparator to control for expectations if we postulate that the clinical effects of 
homoeopathy are placebo effects (Shang et al., 2005). A comparison of this sort could be 
performed in a double-blind design, but to enhance the effect of expectations about the 
treatment, it should be performed in open label, or better, in a four-arm design using 
antidepressants, homeopathy, blinding and open-label, in a latin square design (Figure 5). 
This design can evaluate both efficacy and effectiveness of antidepressant and homeopathy 
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(i.e. placebo). Nevertheless, it is prone to “unblinding” and the randomisation process does 
not take patient preferences into account between antidepressant and alternative medicine, and 
it can interfere with the treatment process. As an example, one study tried to compare 
homeopathy to fluoxetine and placebo in primary care, but failed because of recruitment 
difficulties, many of them linked to patient preferences (Katz et al., 2005). Indeed, this design 
can only meaningfully be applied in those depressed patients who feel that either anti-
depressants or homeopathic anti-depressants could potentially work for their disorder. This 
results in a selection bias, with a restriction of the target population, and can in fact go against 
the concept of effectiveness. This is also the case for sophisticated designs ensuring internal 
validity such as the “balanced placebo trial design”. Recommendations concerning external 
validity are thus necessary. 
2.3. Enabling extrapolation of RCT results 
The external validity of antidepressant studies should be improved 
 
 
Recruitment difficulties arising from patient preferences can lead to a selection bias, yielding 
a non-representative sample of patients, and affect external validity. At the very least, patients 
who have been screened, patients who are eligible and patients who refuse to participate 
should be identified (Moher et al., 2001; Schulz et al., 2010). An interesting alternative is to 
perform a randomised trial with patient preference arms (for patients who agree to 
randomisation, treatment is allocated by randomisation, and for patients who refuse 
randomisation but agree to participate, a choice of treatment is offered). Treatment and 
follow-up are identical in the different groups (Brewin and Bradley, 1989; Chilvers et al., 
2001; Howard and Thornicroft, 2006). This has been proposed for homeopathy (Figure 6) 
(Katz et al., 2005). This type of design directly synchronizes a randomized controlled trial and 
an observational study to generate alternative evidence for assessing antidepressant drug 
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treatment. The double-blind design makes it possible to control for the indication bias, and the 
two preference arms make it possible to partly reduce the selection bias introduced by the 
randomization process. A simple method of analysis is the use of a model with the principal 
outcome as the dependent variable and treatment, design, and treatment-design interaction as 
explanatory variables. Nevertheless a design of this type requires an even larger number of 
patients than a RCT and the analysis should be interpreted with caution because of the 
potential influence of unmeasured confounders (Gemmell and Dunn, 2011). 
As the use of restrictive eligibility criteria limits the scope for generalising RCT results, 
populations in the next generation of (sophisticated) RCTs should differ from the target 
populations of “real-life” depressive patients as little as possible. Studies among primary care 
patients are needed. The only inclusion criterion should be “patient needing an antidepressant 
for depression”. The only exclusion criterion should be “contraindication of the treatment”. 
Using current suicidal ideation as an exclusion criterion could be argued for from an ethical 
point of view. But depressed patients who are assigned to a placebo in antidepressant clinical 
trials are not at greater risk for suicide than those assigned to active treatment (Khan et al., 
2000) whereas patients assigned to antidepressant treatment could well be at greater risk 
(Fergusson et al., 2005). Moreover, these patients are treated with antidepressant in “real life” 
and antidepressants are not studied in these particular patients.  
To assess whether the patients included are truly representative of patients treated in a real-
life setting, we suggest comparing them with registries for their principal clinical and socio-
demographical characteristics. 
A study of effectiveness should last at least 6 months after patient remission to obtain more 
information on the longitudinal effect of antidepressants. Large observational studies 
comparing antidepressants to usual care or to alternative medicine are needed, because they 
have other characteristics that make them useful sources of evidence, in that they tend to last 
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longer and to enrol more patients than do randomized trials (Bluhm, 2009). Statistical 
modelling should enable adjustment on confounding factors (Concato and Horwitz, 2004; 
Lawlor et al., 2004) which should be prespecified in the protocol and assessed with as little 
measurement error as possible to avoid misclassification bias (Mertens, 1993).  
Conclusion 
 
Methodological alternatives to the orthodox RCT should be developed to interpret results 
accurately and ensure internal and external validity. Some are simple and could be 
implemented in RCT easily. Others are sophisticated and raise ethical issues because they 
involve temporary deception of the patient. Nevertheless, improvements in study design for 
antidepressant effectiveness assessment are needed to further knowledge, to improve patient 
care and to determine what costs health authorities should cover. It is a challenge to develop 
study designs addressing the inevitable tension between internal and external validity, which 
can often appear as contradictory. The methodological tools presented here can be useful. The 
concept of antidepressant effectiveness should be developed along different axes and based on 
a convergence of arguments from a range of different study designs.  
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Studies Optimistic bias ITTLOCF OC Attrition = failure Maximal bias  
Sheehan 3.35  [2.32; 4.84] 1.34  [0.96; 1.87]        1.58  [1.09; 2.28] 1.52  [0.98; 2.37]        0.56  [0.41; 0.75] 
Rudolph 4.12  [2.71; 6.26] 1.66  [1.19; 2.32]    1.71  [1.16; 2.52]        1.77  [1.13; 2.78]        0.51  [0.41; 0.65]       
Mendels 2.02  [1.54; 2.66]       1.27  [0.99; 1.63]       1.31  [1.03; 1.65]       1.44  [1.08; 1.91]       0.82  [0.69; 0.98] 
WXL101497 1.67  [1.39; 2.00]       1.38  [1.15; 1.67]       1.34  [1.12; 1.60]       1.38  [1.14; 1.69]       1.03  [0.87; 1.21] 
AK130940 1.82  [1.53; 2.16]       1.33  [1.11; 1.59]       1.31  [1.11; 1.55]       1.30  [1.06; 1.58]       0.87  [0.74. 1.02] 
Total 2.31  [1.75; 3.06] 1.36  [1.23; 1.51] 1.36  [1.23; 1.50] 1.39  [1.24; 1.57] 0.74  [0.59; 0.94] 
 
Table 1: Meta-analysis of response rates using a random effect model of 5 venlafaxine versus placebo studies 
using different hypothesis about missing data. Data were extracted from our previous meta-analysis: out of 26 
randomised double-blind trials, five studies on venlafaxine versus placebo had extractable data. Meta-analyses of 
response rates using a random effect model were performed under different hypotheses about missing data. Four 
situations were considered: 
- Optimistic bias analysis: non-assessed patients are recorded as in remission if they belong to the antidepressant 
group and as having not responded if they belong to the placebo group; 
- ITTLOCF: patient status is derived from the LOCF method on continuous outcomes; 
- OC: observed case analysis; 
- Attrition = failure: non-assessed patient are recorded as not having responded in both groups; 
- Maximum bias: non-assessed patients are recorded as in remission if they belong to the placebo group and as 
not having responded if they belong to the antidepressant group. 
Results are presented as relative risk. Positive relative risk favours venlafaxine and negative relative risk favours 
placebo.  
This example illustrates the uncertainty that arises from missing data when assessing antidepressant effect, which 
can vary from a marked superiority of antidepressants over placebo to a superiority of placebo over 
antidepressants, depending on the imputation method used for missing data. 
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Outcome measurement  
Is a clinician-version evaluations used?   
 Yes 26 (100%) 
 No 0 (0%) 
Is a self-administered questionnaire used?   
 Yes 16 (62 %) 
 No 10 (38 %) 
Is an ecological measure used?   
 Yes 0 (0%) 
 No 26 (100%) 
Attrition and its management  
Percent of patients failing to complete the study  0.14, 0.25, 0.33, 0.37, 0.50 (NA = 3) 
Is last observation carried forward method used?   
 Yes 25 (96 %) 
 No 1 (4 %) 
Is a mixed model used?   
 Yes 1 (4 %) 
 No 25 (96 %) 
Is complete case analysis used?   
 Yes 7 (27 %) 
 No 19 (73 %) 
Response rate in placebo group and internal validity  
Percentages  of responders 0.26, 0.34, 0.41, 0.48, 0.63 (NA = 4) 
Is the “unblinding” phenomena evaluated?   
 Yes 0 (0%) 
 No 26(100%) 
External validity of RCTs in Major Depressive Disorder  
What category of patients is studied? (NA = 2)  
  Inpatients 3 (11.5 %) 
  Outpatients 18 (69%) 
  Outpatients in Primary Care 3 (11.5 %) 
Is a severity score used as an inclusion criterion?   
 Yes 26 (100 %) 
 No 0 (0 %) 
Is a treatment response during placebo lead-in period a non-inclusion 
criterion? (NA = 1)  
 Yes 22 (88 %) 
 No 3 (12 %) 
Study duration (months) 4, 6, 8,12, 13  (NA = 1) 
Meta-analysis limitations  
Is there an industry sponsorship in the study? (NA = 2)  
 Yes 24 (100 %) 
 No 0 (0%) 
 
Table 2: Descriptive analysis of the 26 randomized controlled trial on venlafaxine or fluoxetine considered in our 
previous meta-analysis. Results are presented as numbers (percent) for qualitative outcomes and as minimum, 
first quartile, median, third quartile, maximum for quantitative outcomes. 
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Figure 1. All placebo responders are antidepressant responders. 
 
 
 
 
 
 
Figure 2. Placebo responders and antidepressant responders overlap each other. A, responders 
in treatment group; B, responders in placebo group. 
 
 
 
 
 
 
 
Figure 3. Balanced-placebo design. Four groups are formed following the combination of 
what the patients are told and what treatment they get. 
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Figure 4. Three-arm RCT in which the patient is deceived. 
 
 
 
Figure 5. Four arm design. Four groups are formed according to the treatment they receive 
and their allocation. The effect of homeopathy is assumed to be a placebo effect. 
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Figure 6. RCT, with patient preference arms. For patients who agreed to randomization, 
treatment is allocated with a randomization strategy. For patients who refused randomization 
but agreed to participate in the trial treatment is given according to their choice. 
 
